- ADVANCE Study Ralinepag (IP receptor agonist)
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 3An IP receptor agonist that is a next-generation, once-a-day oral therapy that targets the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).
LEARN MORE Close - Genetically-Enhanced Mesenchymal stem cells (GEM)
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
SepsisStatus
Phase 1
Menu